Cargando…

Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides

A series of seventeen hitherto unknown ANP analogs bearing the (E)-but-2-enyl aliphatic side chain and modified heterocyclic base such as cytosine and 5-fluorocytosine, 2-pyrazinecarboxamide, 1,2,4-triazole-3-carboxamide or 4-substituted-1,2,3-triazoles were prepared in a straight approach through a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Manabu, Roy, Vincent, McBrayer, Tamara R., Whitaker, Tony, Urbina-Blanco, Cesar, Nolan, Steven P., Balzarini, Jan, Snoeck, Robert, Andrei, Graciela, Schinazi, Raymond F., Agrofoglio, Luigi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. Published by Elsevier Masson SAS 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111275/
https://www.ncbi.nlm.nih.gov/pubmed/23911854
http://dx.doi.org/10.1016/j.ejmech.2013.06.053
_version_ 1783513252846632960
author Hamada, Manabu
Roy, Vincent
McBrayer, Tamara R.
Whitaker, Tony
Urbina-Blanco, Cesar
Nolan, Steven P.
Balzarini, Jan
Snoeck, Robert
Andrei, Graciela
Schinazi, Raymond F.
Agrofoglio, Luigi A.
author_facet Hamada, Manabu
Roy, Vincent
McBrayer, Tamara R.
Whitaker, Tony
Urbina-Blanco, Cesar
Nolan, Steven P.
Balzarini, Jan
Snoeck, Robert
Andrei, Graciela
Schinazi, Raymond F.
Agrofoglio, Luigi A.
author_sort Hamada, Manabu
collection PubMed
description A series of seventeen hitherto unknown ANP analogs bearing the (E)-but-2-enyl aliphatic side chain and modified heterocyclic base such as cytosine and 5-fluorocytosine, 2-pyrazinecarboxamide, 1,2,4-triazole-3-carboxamide or 4-substituted-1,2,3-triazoles were prepared in a straight approach through an olefin acyclic cross metathesis as key synthetic step. All novel compounds were evaluated for their antiviral activities against a large number of DNA and RNA viruses including herpes simplex virus type 1 and 2, varicella zoster virus, feline herpes virus, human cytomegalovirus, hepatitis C virus (HCV), HIV-1 and HIV-2. Among these molecules, only compound 31 showed activity against human cytomegalovirus in HEL cell cultures with at EC(50) of ∼10 μM. Compounds 8a, 13, 14, and 24 demonstrated pronounced anti-HCV activity without significant cytotoxicity at 100 μM.
format Online
Article
Text
id pubmed-7111275
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elsevier Masson SAS. Published by Elsevier Masson SAS
record_format MEDLINE/PubMed
spelling pubmed-71112752020-04-02 Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides Hamada, Manabu Roy, Vincent McBrayer, Tamara R. Whitaker, Tony Urbina-Blanco, Cesar Nolan, Steven P. Balzarini, Jan Snoeck, Robert Andrei, Graciela Schinazi, Raymond F. Agrofoglio, Luigi A. Eur J Med Chem Original Article A series of seventeen hitherto unknown ANP analogs bearing the (E)-but-2-enyl aliphatic side chain and modified heterocyclic base such as cytosine and 5-fluorocytosine, 2-pyrazinecarboxamide, 1,2,4-triazole-3-carboxamide or 4-substituted-1,2,3-triazoles were prepared in a straight approach through an olefin acyclic cross metathesis as key synthetic step. All novel compounds were evaluated for their antiviral activities against a large number of DNA and RNA viruses including herpes simplex virus type 1 and 2, varicella zoster virus, feline herpes virus, human cytomegalovirus, hepatitis C virus (HCV), HIV-1 and HIV-2. Among these molecules, only compound 31 showed activity against human cytomegalovirus in HEL cell cultures with at EC(50) of ∼10 μM. Compounds 8a, 13, 14, and 24 demonstrated pronounced anti-HCV activity without significant cytotoxicity at 100 μM. Elsevier Masson SAS. Published by Elsevier Masson SAS 2013-09 2013-07-04 /pmc/articles/PMC7111275/ /pubmed/23911854 http://dx.doi.org/10.1016/j.ejmech.2013.06.053 Text en Copyright © 2013 Elsevier Masson SAS. Published by Elsevier Masson SAS All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Hamada, Manabu
Roy, Vincent
McBrayer, Tamara R.
Whitaker, Tony
Urbina-Blanco, Cesar
Nolan, Steven P.
Balzarini, Jan
Snoeck, Robert
Andrei, Graciela
Schinazi, Raymond F.
Agrofoglio, Luigi A.
Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
title Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
title_full Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
title_fullStr Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
title_full_unstemmed Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
title_short Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
title_sort synthesis and broad spectrum antiviral evaluation of bis(pom) prodrugs of novel acyclic nucleosides
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111275/
https://www.ncbi.nlm.nih.gov/pubmed/23911854
http://dx.doi.org/10.1016/j.ejmech.2013.06.053
work_keys_str_mv AT hamadamanabu synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT royvincent synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT mcbrayertamarar synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT whitakertony synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT urbinablancocesar synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT nolanstevenp synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT balzarinijan synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT snoeckrobert synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT andreigraciela synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT schinaziraymondf synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides
AT agrofoglioluigia synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides